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Background: Vascular complications (VC) after transfemoral (TF) TAVR are frequent and may be associated with unfavorable clinical outcomes. 
However, there is a paucity of data from well-conducted studies regarding the incidence, predictors and impact of VC on long-term prognosis after 
TF-TAVR.
Methods: From the pivotal randomized control PARTNER trial, a total of 423 pts (179 from the inoperable cohort B pts and 244 from the operable 
high-risk cohort A pts) were randomly assigned to TF-TAVR or control therapy. First generation Edwards-Sapien valves (23mm or 26mm diameter) and 
delivery systems were used, via either a 22 or 24 Fr sheath. Thirty-day rates of major and minor VC (modified VARC definitions), predictors and effect 
on 1-year mortality were assessed.
Results: Vessel access and closure were primarily done by surgical cut-down in both cohort B (83.4%) and cohort A (71.9%) pts. The 30-day rate 
of all VC was significantly higher in cohort B compared to cohort A pts [30.7% (55/179) vs 22.1% (54/244) p=0.03], but the rate of major VC was 
only slightly higher in cohort B pts [16.8% (30/179) vs.13.5% (33/244), p=0.35]. Among the 55 cohort B and the 54 cohort A pts with VC, vascular 
dissection (38% vs 40%), site hematoma (25% vs 17%) and vessel perforation (15% vs 20%) were the most frequent modes of presentation. Cohort 
B pts with major VC had a higher risk of death at 1 year (45.2% vs. 27.7%, HR:1.91 95%CI [1.04,3.51], p=0.03) compared to pts with no major VC. 
However, cohort A pts with major VC had a non-significant increase in 1-year mortality (29.6% vs. 21.0%, HR:1.63 95%CI [0.82,3.23], p=0.161). 
Independent predictors of major VC among pts from both cohorts were female gender (HR:3.00, p<0.001), younger age (HR:1.04, p=0.02) and lower 
BMI (HR:1.05, p=0.01). A Cox proportional hazard analysis including pts from both cohorts identified major VC as an independent predictor of 1-year 
mortality (HR: 2.03, p=0.027).
Conclusion: VC were frequent after TF-TAVR in the PARTNER trial using first generation devices and were associated with a high 1-year mortality. 
However, the incidence and the impact of major VC on 1-year mortality decreased with lower risk populations and with increased operator 
experience at the enrolling sites.
